论文部分内容阅读
目的探讨乳腺癌新辅助化疗前后MCM7蛋白的表达状况,分析其与化疗效果的关系。方法采用免疫组织化学法检测55例乳腺癌新辅助化疗前后标本中MCM7的表达。结果新辅助化疗有效率为76.36%。化疗前MCM7蛋白阳性表达显著高于化疗后(P<0.01)。化疗有效组(42例增殖期)MCM7蛋白阳性表达显著高于无效组(13例静止期)(P<0.01)。结论ET方案新辅助化疗有较好的疗效,可能通过抑制MCM7蛋白的表达来阻止乳腺癌细胞的增殖。MCM7蛋白高表达者化疗更为敏感,MCM7可作为临床指导乳腺癌化疗并预测化疗敏感性的分子生物学指标。
Objective To investigate the expression of MCM7 protein before and after neoadjuvant chemotherapy in breast cancer, and to analyze its relationship with the effect of chemotherapy. Methods Immunohistochemistry was used to detect the expression of MCM7 in 55 cases of breast cancer before and after neoadjuvant chemotherapy. Results neoadjuvant chemotherapy was 76.36%. The positive expression of MCM7 protein before chemotherapy was significantly higher than that after chemotherapy (P <0.01). The positive expression rate of MCM7 in chemotherapy-effective group (42 cases of proliferative phase) was significantly higher than that in ineffective group (13 cases of quiescent) (P <0.01). Conclusion ET neoadjuvant chemotherapy has better curative effect, which may prevent the proliferation of breast cancer cells by inhibiting the expression of MCM7 protein. Chemotherapy of MCM7 overexpression is more sensitive and MCM7 can be used as a molecular biological indicator to guide breast cancer chemotherapy and predict chemosensitivity.